Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Biomaterials ; 107: 74-87, 2016 11.
Article in English | MEDLINE | ID: mdl-27614160

ABSTRACT

Glioblastoma multiforme (GBM) is among the most aggressive cancers associated with massive infiltration of peritumoral parenchyma by migrating tumor cells. The infiltrative nature of GBM cells, the intratumoral heterogeneity concomitant with redundant signaling pathways likely underlie the inability of conventional and targeted therapies to achieve long-term remissions. In this respect, microRNAs (miRNAs), which are endogenous small non-coding RNAs that play a role in cancer aggressiveness, emerge as possible relevant prognostic biomarkers or therapeutic targets for treatment of malignant gliomas. We previously described a tissue model of GBM developing into a stem cell-derived human Engineered Neural Tissue (ENT) that allows the study of tumor/host tissue interaction. Combined with high throughput sequencing analysis, we took advantage of this human and integrated tissue model to understand miRNAs regulation. Three miRNAs (miR-340, -494 and -1293) active on cell proliferation, adhesion to extracellular matrix and tumor cell invasion were identified in GBM cells developing within ENT, and also confirmed in GBM biopsies. The components of miRNAs regulatory network at the transcriptional and the protein level have been also revealed by whole transcriptome analysis and Tandem Mass Tag in transfected GBM cells. Notably, miR-340 has a clinical relevance and modulates the expression of miR-494 and -1293, emphasizing its biological significance. Altogether, these findings demonstrate that human tissue engineering modeling GBM development in neural host tissue is a suitable tool to identify active miRNAs. Collectively, our study identified miR-340 as a strong modulator of GBM aggressiveness which may constitute a therapeutic target for treatment of malignant gliomas.


Subject(s)
Glioblastoma/metabolism , Glioblastoma/pathology , MicroRNAs/metabolism , Neural Stem Cells/pathology , Tissue Engineering/methods , Cell Adhesion , Cell Proliferation , Cells, Cultured , Gene Expression Regulation, Neoplastic , Humans , Neoplasm Invasiveness , Signal Transduction
3.
Ann Rheum Dis ; 63(4): 415-9, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15020336

ABSTRACT

BACKGROUND: Anti-filaggrin antibodies (AFA) are among the most specific antibodies for rheumatoid arthritis, so procedures for their detection should be included in early biological diagnoses. AFA can be detected by indirect immunofluorescence (anti-keratin antibodies, AKA) or by new enzyme immunoassays (EIA). Their comparative performance needs to be established. OBJECTIVE: To compare these technical procedures to optimise the serological diagnosis of rheumatoid arthritis. METHODS: Results obtained using AKA and EIA were compared in 271 sera from 140 patients with rheumatoid arthritis at various stages, 98 patients with other autoimmune diseases, and 33 healthy subjects. EIA were successively undertaken with citrullinated linear filaggrin peptide (home made EIA) or cyclic citrullinated peptide (CCP2, commercial kits). Rheumatoid factor (RF) was assessed by EIA in all patients. RESULTS: Anti-CCP2 kits showed the best sensitivity and specificity (65% and 96%, respectively). Among the 140 patients with rheumatoid arthritis, those with very recent disease (less than six months' duration, n = 21) were studied as a separate group. In this group, the sensitivity of anti-CCP2 kits decreased to approximately 50%. Nevertheless this assay remained the most accurate when compared with AKA or home made EIA using linear filaggrin peptides. The combination of anti-CCP2 and RF only slightly increased the sensitivity of the diagnosis of very early rheumatoid arthritis. CONCLUSIONS: Kits using citrullinated cyclic peptides (CCP2) were more suitable than either AKA or EIA using linear filaggrin peptides for the diagnosis of early rheumatoid disease.


Subject(s)
Antibodies/blood , Arthritis, Rheumatoid/diagnosis , Intermediate Filament Proteins/immunology , Arthritis, Rheumatoid/blood , Arthritis, Rheumatoid/immunology , Biomarkers/blood , Citrulline/immunology , Filaggrin Proteins , Fluorescent Antibody Technique, Indirect/methods , Humans , Immunoenzyme Techniques/methods , Immunoglobulin G/blood , Keratins/immunology , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/immunology , Reagent Kits, Diagnostic , Rheumatoid Factor/analysis , Rheumatoid Factor/immunology , Sensitivity and Specificity , Sjogren's Syndrome/blood , Sjogren's Syndrome/diagnosis , Sjogren's Syndrome/immunology
4.
J Neuroimmunol ; 129(1-2): 232, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12161040

ABSTRACT

We investigated the effects of interferon beta-1a (IFN beta-1a) on specific response towards two immunodominant MBP peptides and on global production of IgG. We evaluated 54 sera from multiple sclerosis (MS) patients at baseline and 1 year after treatment. We did not observe any modification of immune response to the MBP peptides but we noted a significant decrease in mean IgG concentrations in patients with progression of the disease but not in stable patients. These results suggest that IFN beta1a restores or maintains a beneficial immune response.


Subject(s)
Down-Regulation/drug effects , Immune System/drug effects , Immunoglobulin G/blood , Immunoglobulin G/drug effects , Interferon-beta/therapeutic use , Multiple Sclerosis/blood , Multiple Sclerosis/drug therapy , Adult , Autoantibodies/blood , Autoantibodies/drug effects , Disease Progression , Down-Regulation/immunology , Epitopes/immunology , Female , Humans , Immune System/immunology , Interferon beta-1a , Male , Middle Aged , Multiple Sclerosis/immunology , Myelin Basic Protein/immunology , Peptide Fragments/immunology , Treatment Outcome
5.
Proc Natl Acad Sci U S A ; 98(18): 10302-7, 2001 Aug 28.
Article in English | MEDLINE | ID: mdl-11517329

ABSTRACT

Activation of CD8(+) cytolytic T lymphocytes (CTLs) by antigen is triggered by the interaction of clonotypic alphabeta T cell receptors (TCRs) with antigenic peptides bound to MHC class I molecules (pMHC complexes). Fluorescent multimeric pMHC complexes have been shown to specifically stain antigen-specific CTLs by directly binding the TCR. In tumor-infiltrating lymphocytes from a melanoma patient we found a high frequency of tyrosinase(368-376) peptide-specific cells as detected by IFN-gamma ELISPOT, without detectable staining with the corresponding A2/peptide multimers. Surprisingly, these T cells were able to lyse tyrosinase(368-376) peptide-pulsed target cells as efficiently as other specific T cells that were stained by multimers. Analysis of the staining patterns under different conditions of incubation time and temperature revealed that these results were explained by major differences in TCR-multimeric ligand interaction kinetics among the clones. Whereas no direct quantitative correlation between antigenic peptide concentration required for CTL effector functions and equilibrium multimer binding was observed interclonally, the latter was profoundly affected by the kinetics of TCR-ligand interaction. More importantly, our data indicate that similar levels of T cell activation can be achieved by independent CD8(+) T cell clonotypes displaying different TCR/pMHC complex dissociation rates.


Subject(s)
HLA-A2 Antigen/metabolism , Interferon-gamma/metabolism , Receptors, Antigen, T-Cell/metabolism , T-Lymphocytes, Cytotoxic/immunology , Clone Cells , Enzyme-Linked Immunosorbent Assay , HLA-A2 Antigen/chemistry , Half-Life , Humans , In Vitro Techniques , Kinetics , Ligands , Lymphocytes, Tumor-Infiltrating/immunology , Macromolecular Substances , Melanoma/immunology , Receptors, Antigen, T-Cell/chemistry
6.
Cancer Res ; 61(15): 5850-6, 2001 Aug 01.
Article in English | MEDLINE | ID: mdl-11479225

ABSTRACT

MAGE-encoded antigens, which are expressed by tumors of many histological types but not in normal tissues, are suitable candidates for vaccine-based immunotherapy of cancers. Thus far, however, T-cell responses to MAGE antigens have been detected only occasionally in cancer patients. In contrast, by using HLA/peptide fluorescent tetramers, we have observed recently that CD8(+) T cells specific for peptide MAGE-A10(254-262) can be detected frequently in peptide-stimulated peripheral blood mononuclear cells from HLA-A2-expressing melanoma patients and healthy donors. On the basis of these results, antitumoral vaccination trials using peptide MAGE-A10(254-262) have been implemented recently. In the present study, we have characterized MAGE-A10(254-262)-specific CD8(+) T cells in polyclonal cultures and at the clonal level. The results indicate that the repertoire of MAGE-A10(254-262)-specific CD8(+) T cells is diverse both in terms of clonal composition, efficiency of peptide recognition, and tumor-specific lytic activity. Importantly, only CD8(+) T cells able to recognize the antigenic peptide with high efficiency are able to lyse MAGE-A10-expressing tumor cells. Under defined experimental conditions, the tetramer staining intensity exhibited by MAGE-A10(254-262)-specific CD8(+) T cells correlates with efficiency of peptide recognition so that "high" and "low" avidity cells can be separated by FACS. Altogether, the data reported here provide evidence for functional diversity of MAGE-A10(254-262)-specific T cells and will be instrumental for the monitoring of peptide MAGE-A10(254-262)-based clinical trials.


Subject(s)
Antibody Affinity/immunology , Melanoma/immunology , Neoplasm Proteins/immunology , T-Lymphocytes, Cytotoxic/immunology , Antibodies, Monoclonal/immunology , Antibodies, Neoplasm/immunology , Antigens, Neoplasm/immunology , Epitopes, T-Lymphocyte/immunology , Flow Cytometry , HLA-A2 Antigen/immunology , Humans , Peptide Fragments/immunology , Tumor Cells, Cultured
7.
J Neuroimmunol ; 117(1-2): 149-55, 2001 Jul 02.
Article in English | MEDLINE | ID: mdl-11431015

ABSTRACT

An increased level of citrullinated myelin basic protein (MBP-C8) has been reported in the brains of multiple sclerosis (MS) patients. However, the involvement of the immune response to post-translational modified MBP in the pathophysiology of MS remains speculative. The aim of this study was to compare the levels of immunoglobulin G antibodies to several MBP epitopes, before and after citrullination, in the cerebrospinal fluid (CSF) and sera of MS patients using enzyme-linked immunosorbent assay (ELISA). We analyzed antibody reactivity against various MBP-peptides in the CSF and sera of 60 MS patients, and 30 patients with other neurological diseases (OND) as controls. The peptides tested were: MBP(75-98) (peptide 1), native (peptide 2) and citrullinated (peptide 3) MBP(108-126) (ARG(122)-->Cit(122)), and native (peptide 4) and citrullinated (peptide 5) MBP(151-170) (ARG(159, 170)-->Cit(159, 170)). All selected peptides could support an immune reactivity in CSF and sera of MS and OND patients. A higher reactivity against peptide 4 was found in the CSF of MS patients compared with OND patients (P<0.0001), but not against citrullinated peptides (peptides 3 and 5). However, we observed that the citrullination state of peptide 2 modified the patterns of immune reactivity more markedly in MS patients (P<0.0001) than in OND patients (P<0.02). Although some MBP epitopes could be a potential target in MS, our data did not demonstrate any difference of antibody response to MBP peptides in their citrullinated forms.


Subject(s)
Citrulline/metabolism , Immunoglobulin G/analysis , Multiple Sclerosis/immunology , Myelin Basic Protein/immunology , Adolescent , Adult , Aged , Amino Acid Sequence , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Molecular Sequence Data , Protein Processing, Post-Translational
8.
Cancer Res ; 61(13): 5153-60, 2001 Jul 01.
Article in English | MEDLINE | ID: mdl-11431354

ABSTRACT

The recent identification of molecularly defined human tumor antigens recognized by autologous CTLs has opened new opportunities for the development of antigen-specific cancer vaccines. Despite extensive work, however, the number of CTL-defined tumor antigens that are suitable targets for generic vaccination of cancer patients is still limited, mostly because of the painstaking and lengthy nature of the procedures currently used for their identification. A novel approach is based on the combined use of combinatorial peptide libraries in positional scanning format (positional scanning synthetic combinatorial peptide libraries, PS-SCLs) and tumor-reactive CTL clones. To validate this approach, we herein analyzed in detail the recognition of PS-SCLs by Melan-A-specific CTL clones. Our results indicate that, at least for some clones, most of the amino acids composing the native antigenic peptide can be identified through the use of PS-SCLs. Interestingly, this analysis also allowed the identification of peptide analogues with increased antigenic activity as well as agonist peptides containing multiple amino-acid substitutions. In addition, biometrical analysis of the data generated by PS-SCL screening allowed the identification of the native ligand in a public database. Overall, these data demonstrate the successful use of PS-SCLs for the identification and optimization of tumor-associated CTL epitopes.


Subject(s)
Epitopes, T-Lymphocyte/immunology , Neoplasm Proteins/immunology , Oligopeptides/immunology , Peptide Library , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Antigens, Neoplasm , Cell Line , Clone Cells , Databases, Factual , Humans , MART-1 Antigen
9.
Clin Cancer Res ; 7(3 Suppl): 766s-772s, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11300471

ABSTRACT

We have shown previously that HLA-A*0201 melanoma patients can frequently develop a CTL response to the cancer testis antigen NY-ESO-1. In the present study, we have analyzed in detail the relative antigenicity and in vitro immunogenicity of natural and modified NY-ESO-1 peptide sequences. The results of this analysis revealed that, although suboptimal for binding to the HLA-A*0201 molecule, peptide NY-ESO-1 157-165 is, among natural sequences, very efficiently recognized by specific CTL clones derived from three melanoma patients. In contrast, peptides NY-ESO-1 157-167 and NY-ESO-1 155-163, which bind very strongly to HLA-A*0201, are recognized less efficiently. In agreement with previous data, substitution of peptide NY-ESO-1 157-165 COOH-terminal C with various other amino acids resulted in a significantly increased binding to HLA-A*0201 molecules as well as in an increased CTL recognition, although variable at the clonal level. Among natural peptides, NY-ESO-1 157-165 and NY-ESO-1 157-167 exhibited good in vitro immunogenicity, whereas peptide NY-ESO-1 155-163 was poorly immunogenic. The fine specificity of interaction between peptide NY-ESO-1 C165A, HLA-A*0201, and T-cell receptor was analyzed at the molecular level using a series of variant peptides containing single alanine substitutions. The findings reported here have significant implications for the formulation of NY-ESO-1-based vaccines as well as for the monitoring of either natural or vaccine-induced NY-ESO-1-specific CTL responses in cancer patients.


Subject(s)
Antigens, Neoplasm , Antigens/metabolism , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , Membrane Proteins , Proteins/metabolism , Binding, Competitive , Cell Separation , Dose-Response Relationship, Drug , Flow Cytometry , HLA-A2 Antigen/metabolism , Humans , Interferon-gamma/metabolism , Melanoma/metabolism , Microscopy, Fluorescence , Peptides/chemistry , Peptides/metabolism , Protein Binding , Tumor Cells, Cultured
10.
Clin Cancer Res ; 7(3 Suppl): 796s-803s, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11300475

ABSTRACT

Peptide-based vaccines are currently being tested for their ability to induce or augment tumor antigen (Ag)-specific CD8+ T-cell responses in cancer patients. Here we report that the frequency of circulating CD8+ T cells directed against the Melan-A/MART-1 Ag increased >20-fold in an HLA-A2 melanoma patient immunized repeatedly with the corresponding antigenic peptide, as assessed by staining with HLA-A2/peptide tetramers. Multiparameter flow cytometric analysis demonstrated that the increase in total Melan-A-specific cell number was accompanied by a marked increase in the proportion of the cells that expressed an activated/memory surface phenotype. As assessed by ELISPOT assays and intracellular staining, the absolute number of Melan-A-specific cells able to secrete IFN-gamma increased >50-fold upon vaccination. When tested directly after cell sorting on the basis of tetramer staining, Melan-A-specific cells were weakly cytolytic but became highly active after in vitro restimulation. Altogether, these results indicate that large numbers of functionally active tumor Ag-specific CD8+ T cells can be obtained and maintained at high levels after in vivo activation by repeated peptide-based vaccination.


Subject(s)
CD8-Positive T-Lymphocytes/metabolism , Cancer Vaccines/chemistry , Melanoma/immunology , Antibodies, Monoclonal/metabolism , Antigens, Neoplasm , Cell Division , Flow Cytometry , Granzymes , Humans , Interferon-gamma/metabolism , Lymphocytes/metabolism , MART-1 Antigen , Melanoma/metabolism , Neoplasm Proteins/chemistry , Neoplasm Proteins/metabolism , Neoplasms/immunology , Neoplasms/metabolism , Peptides/metabolism , Phenotype , Serine Endopeptidases/metabolism , Time Factors
11.
Cancer Res ; 61(5): 2047-54, 2001 Mar 01.
Article in English | MEDLINE | ID: mdl-11280765

ABSTRACT

HLA-A2+ melanoma patients develop naturally a strong CD8+ T cell response to a self-peptide derived from Melan-A. Here, we have used HLA-A2/peptide tetramers to isolate Melan-A-specific T cells from tumor-infiltrated lymph nodes of two HLA-A2+ melanoma patients and analyzed their TCR beta chain V segment and complementarity determining region 3 length and sequence. We found a broad diversity in Melan-A-specific immune T-cell receptor (TCR) repertoires in terms of both TCR beta chain variable gene segment usage and clonal composition. In addition, immune TCR repertoires selected in the patients were not overlapping. In contrast to previously characterized CD8+ T-cell responses to viral infections, this study provides evidence against usage of highly restricted TCR repertoire in the natural response to a self-differentiation tumor antigen.


Subject(s)
Antigens, Neoplasm/immunology , Melanoma/immunology , Neoplasm Proteins/immunology , Peptide Fragments/immunology , T-Lymphocytes, Cytotoxic/immunology , Amino Acid Sequence , Base Sequence , Complementarity Determining Regions/immunology , Epitopes, T-Lymphocyte/immunology , HLA-A2 Antigen/immunology , Humans , Immunodominant Epitopes/immunology , Immunoglobulin Variable Region/immunology , Lymph Nodes/immunology , Lymph Nodes/pathology , MART-1 Antigen , Molecular Sequence Data , Receptors, Antigen, T-Cell, alpha-beta/immunology
12.
Cancer Res ; 61(2): 509-12, 2001 Jan 15.
Article in English | MEDLINE | ID: mdl-11212242

ABSTRACT

MAGE genes encode tumor-specific shared antigens that are among the most interesting candidates for cancer vaccines. Despite extensive studies, however, CD8+ T-cell responses to MAGE-derived epitopes have been detected only occasionally in cancer patients, even after vaccination. In contrast with these findings, we report here that HLA-A2 melanoma patients respond frequently to the recently identified peptide MAGE-A10(254-262). Indeed, as assessed by staining with fluorescent HLA-A2/peptide MAGE-A10(254-262) tetramers, CD8+ T cells directed against this peptide were readily detectable in a large proportion of HLA-A2+ melanoma patients. These results provide new insight into the immunogenicity of MAGE antigens and underline the potential usefulness of MAGE-A10 peptide-based cancer vaccines.


Subject(s)
Melanoma/immunology , Neoplasm Proteins/immunology , Oligopeptides/immunology , T-Lymphocytes, Cytotoxic/immunology , Animals , Antibodies, Monoclonal/pharmacology , Antigens, Neoplasm , COS Cells , Cytotoxicity, Immunologic/drug effects , DNA, Recombinant , Dose-Response Relationship, Drug , HLA-A2 Antigen/genetics , HLA-A2 Antigen/immunology , Humans , Neoplasm Proteins/chemistry , Neoplasm Proteins/genetics , Oligopeptides/genetics , Oligopeptides/pharmacology , Plasmids/genetics , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/metabolism
13.
J Immunol ; 165(12): 7253-61, 2000 Dec 15.
Article in English | MEDLINE | ID: mdl-11120859

ABSTRACT

Recent studies have shown that CTL epitopes derived from tumor-associated Ags can be encoded by both primary and nonprimary open reading frames (ORF). In this study we have analyzed the HLA-A2-restricted CD8(+) T cell response to a recently identified CTL epitope derived from an alternative ORF product of gene LAGE-1 (named CAMEL), and the highly homologous gene NY-ESO-1 in melanoma patients. Using MHC/peptide tetramers we detected CAMEL(1-11)-specific CD8(+) T cells in peptide-stimulated PBMC as well as among tumor-infiltrated lymph node cells from several patients. Sorting and expansion of tetramer(+) CD8(+) T cells allowed the isolation of tetramer(bright) and tetramer(dull) populations that specifically recognized the peptide Ag with high and low avidity, respectively. Remarkably, only high avidity CAMEL-specific CTL were able to recognize Ag-expressing tumor cells. A large series of HLA-A2-positive melanoma cell lines was characterized for the expression of LAGE-1 and NY-ESO-1 mRNA and protein and tested for recognition by CAMEL-specific CTL as well as CTL that recognize a peptide (NY-ESO-1(157-165)) encoded by the primary ORF products of the LAGE-1 and NY-ESO-1 genes. This analysis revealed that tumor-associated CD8(+) T cell epitopes are simultaneously and efficiently generated from both primary and nonprimary ORF products of LAGE-1 and NY-ESO-1 genes and, importantly, that this occurs in the majority of melanoma tumors. These findings underscore the in vivo immunological relevance of CTL epitopes derived from nonprimary ORF products and support their use as candidate vaccines for inducing tumor specific cell-mediated immunity against cancer.


Subject(s)
Antigen Presentation , Antigens, Neoplasm/metabolism , Epitopes, T-Lymphocyte/metabolism , Melanoma/immunology , Membrane Proteins , Open Reading Frames/immunology , Proteins/immunology , Proteins/metabolism , T-Lymphocytes, Cytotoxic/immunology , Animals , Antigen Presentation/genetics , Antigens, Neoplasm/genetics , Antigens, Surface , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/metabolism , COS Cells , Clone Cells , Cytotoxicity Tests, Immunologic , Epitopes, T-Lymphocyte/genetics , Gene Expression Regulation/immunology , Genetic Vectors/immunology , Genetic Vectors/metabolism , HLA-A2 Antigen/immunology , HLA-A2 Antigen/metabolism , Humans , Melanoma/genetics , Peptide Fragments/immunology , Peptide Fragments/metabolism , Protein Binding/immunology , Protein Biosynthesis , Proteins/genetics , Sequence Homology, Nucleic Acid , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism , T-Lymphocytes, Cytotoxic/metabolism , Transfection , Tumor Cells, Cultured
14.
Cancer Res ; 60(16): 4499-506, 2000 Aug 15.
Article in English | MEDLINE | ID: mdl-10969798

ABSTRACT

Cancer testis (CT) antigens are particularly interesting candidates for cancer vaccines. However, T-cell reactivity to CT antigens has been detected only occasionally in cancer patients, even after vaccination. A new group of CT antigens has been recently identified using the SEREX technique based on immunoscreening of tumor cDNA expression libraries with autologous sera. We have used fluorescent HLA-A2/peptide tetramers containing an optimized antigenic peptide to directly identify HLA-A2-restricted CD8+ T cells specific for the SEREX-defined CT antigen NY-ESO-1 in melanoma patients. High frequencies of NY-ESO-1-specific CD8+ T cells were readily detected in peptide-stimulated peripheral blood mononuclear cells as well as in lymphocytes infiltrating melanoma lesions from patients with measurable antibody responses to NY-ESO-1. NY-ESO-1-specific CD8+ T cells were also detectable in peptide-stimulated peripheral blood mononuclear cells from some seronegative patients. Whereas the frequencies of NY-ESO-1-specific CD8+ T cells in circulating lymphocytes were usually below the limit of detection by tetramer staining, the presence of NY-ESO-1 CD8+ T cells displaying a memory phenotype was clearly detectable ex vivo in blood from a seropositive patient over an extended period of time. These results indicate that sustained CD8+ T-cell responses to CT antigens can naturally occur both locally and systemically in melanoma patients.


Subject(s)
Antigens, Neoplasm/immunology , CD8-Positive T-Lymphocytes/immunology , Cancer Vaccines/immunology , HLA-A2 Antigen/immunology , Lymphocyte Activation/immunology , Melanoma/immunology , Membrane Proteins , Proteins/immunology , Amino Acid Sequence , Epitopes, T-Lymphocyte/immunology , Humans , Lymphocytes, Tumor-Infiltrating/immunology , Male , Melanoma/blood , Melanoma/therapy , Peptide Fragments/immunology , T-Lymphocytes, Cytotoxic/immunology , Testis/immunology
15.
J Immunol ; 165(1): 533-8, 2000 Jul 01.
Article in English | MEDLINE | ID: mdl-10861093

ABSTRACT

The assessment of the TCR repertoire expressed by tumor-specific CD8+ T lymphocytes has been hampered to date by the difficulty of targeting the analysis to lymphocytes directed against a single epitope. In the present study we have used fluorescent A2/Melan-A tetramers in conjunction with anti-CD8 and anti-TCR beta-chain variable (BV) mAbs to analyze by flow cytometry the BV segment usage by Melan-A-specific CD8+ T cells in tumor-infiltrated lymph nodes (TILN) and tumor-infiltrating lymphocytes (TIL) from A2 melanoma patients. Analysis of TILN populations revealed small proportions of A2/Melan-A tetramer+ cells expressing many different BV together with over-representation of A2/Melan-A tetramer+ cells expressing certain BVs. The BV usage by A2/Melan-A tetramer+ lymphocytes in TIL was more restricted than that in TILN. Moreover, the predominant BV segments were quite distinct in populations derived from different patients. A2/Melan-A tetramer+ cells expressing the dominant BVs found in TILN could also be found in the corresponding peptide-stimulated autologous PBMC, although A2/Melan-A tetramer+ lymphocytes expressing additional BVs were also identified. Together, these results suggest that a large and diverse repertoire of Melan-A-specific T cells using different BV TCR segments is available in A2 melanoma patients.


Subject(s)
CD8-Positive T-Lymphocytes/metabolism , Epitopes, T-Lymphocyte/metabolism , Gene Rearrangement, beta-Chain T-Cell Antigen Receptor , Genes, T-Cell Receptor beta , Melanoma/immunology , Neoplasm Proteins/immunology , Adult , Aged , Antigens, Neoplasm/metabolism , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/pathology , Humans , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Lymphocyte Activation/immunology , Lymphocyte Count , Lymphocytes, Tumor-Infiltrating/immunology , Lymphocytes, Tumor-Infiltrating/metabolism , Lymphocytes, Tumor-Infiltrating/pathology , MART-1 Antigen , Melanoma/metabolism , Melanoma/pathology , Middle Aged , Neoplasm Proteins/biosynthesis , Peptide Fragments/immunology , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...